Navigation Links
Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group

Major Bleeding in Patients Treated for Acute Coronary Syndromes (ACS) Nearly Triples the Risk of Death at One Year

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- One-year findings from the landmark ACUITY trial show that acute coronary syndrome (ACS) patients in the "Angiomax(R) (bivalirudin) alone" treatment group had similar rates of ischemic clinical outcomes compared with more complicated standard therapy, confirming previous findings, which showed similar ischemia at 30 days, and nearly 50% fewer episodes of major bleeding. At one year, the mortality rate of patients treated in the Angiomax alone treatment group was 3.8%, compared to 4.4% in the control treatment group. A separate analysis found that, in patients with ACS, having a major bleeding episode within 30 days following treatment nearly triples the risk of death up to one year later, making major bleeding a more powerful predictor of mortality than even a heart attack.

The ACUITY one-year results were presented as late-breaking findings by investigators for the first time here at the i2 Summit at the 56th Annual Scientific Session of the of Cardiology. Collectively, the data showed that ACUITY met all primary one-year endpoints and confirmed previously published 30-day findings. The Medicines Company markets Angiomax, an anti-clotting agent, in the United States.

"Our findings are important because they demonstrate that in high risk patients with ACS, Angiomax, the simplest and least expensive regimen, results in the overall best clinical outcomes," said ACUITY's principal investigator, Gregg W. Stone, MD, professor of medicine and director of cardiovascular research and education at Medical Center's Center for Interventional Vascular Therapy, and chairman of the Cardiovascular Research Foundation.

Study Findings

The one-year ACUITY analysis showed that treatment in the Angiomax(R)(bivalirudin) alone group resulted in comp
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
6. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
7. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
8. EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial at 47th Annual NCDEU Meeting
9. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
10. Prana Biotechnology Presents New Key Findings on PBT2
11. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
Post Your Comments:
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
(Date:12/22/2014)... Inc. (NASDAQ: CYBX ), a global leader in ... announced it will participate in the 33 rd  Annual ... San Francisco . Dan ... at 11:00 AM Pacific Time.  A live audio webcast of ... Relations link on the Cyberonics home page at www.cyberonics.com ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... Group, Inc. (NYSE: HGR ) announced today that it ... March 31, 2011, on Thursday, April 28, 2011. The ... the quarter ended March 31, 2011 on Wednesday, April 27, 2011 ... these results is scheduled to begin at 9:00 a.m., EDT, on ...
... (Pink Sheets: IMJX ), today officially reported ... highlighted the key business accomplishment during the past fiscal ... 2010 demonstrated significant improvement from 2009, with total sales ... all of 2010, both a significant improvement over the ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces First Quarter 2011 Earnings Release Conference Call 2ImageXpres Posts OTC Markets 2010 Annual Report 2ImageXpres Posts OTC Markets 2010 Annual Report 3
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... in on a "fountain of youth" drug that can delay ... adults, a new study suggests. Seniors received a significant ... targets a genetic signaling pathway linked to aging and immune ... The experimental medication, a version of the drug rapamycin, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 “ SmileStix ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... to create personal stickers. , The old saying goes, “A ... lot of words that can describe a single image, because ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... strangulation game in 2005-2006 , , THURSDAY, Feb. 14 (HealthDay ... playing the "choking game" since 1995, a new government ... "pass out game," "scarf game," "space monkey" and other ... oneself or another with hands or some sort of ...
... Next Before Final Version is,Voted On, BETHESDA, Md., ... "national need" will include occupational,therapists if an agreement made ... AOTA staff worked fast and furiously to have the ... was able to have Representative Tom,Price of Georgia ask ...
... team of researchers was able to identify the location ... through analysis of genetic material (DNA) from members of ... from autosomal dominant juvenile cataract. The corresponding protein belongs ... molecules across cell mem-branes. Surprisingly, this genetic defect may ...
... , , THURSDAY, Feb. 14 (HealthDay News) -- A new ... found in the U.S.-banned insecticide DDT accelerates the growth ... in the open access journal Breast Cancer Research ... of a hormone that would otherwise help inhibit growth ...
... of the presidential nomination campaign, some candidates health care ... phrase socialized medicine has been used to attack health ... by the Harvard Opinion Research Program at the Harvard ... that Americans are split on whether a socialized medical ...
... available for all Minnesotans, MINNEAPOLIS, Feb. 14 ... such as a birthday or holiday as a "quit ... perfect day to,quit smoking for that special someone, and ... Services from ClearWay,Minnesota(SM)., Some romantic benefits of quitting, ...
Cached Medicine News:Health News:'Choking Game' Turned Deadly for 82 Youths 2Health News:'Choking Game' Turned Deadly for 82 Youths 3Health News:AOTA Gets Profession Addressed on House Floor in Federal Loan Repayment Bill 2Health News:New cataract gene discovered 2Health News:DDT Compound Speeds Breast Cancer Growth 2Health News:Poll finds Americans split by political party over views on socialized medicine 2Health News:Poll finds Americans split by political party over views on socialized medicine 3Health News:QUITPLAN(R) Services Can Help Make Valentine's Day Smoke-Free 2Health News:QUITPLAN(R) Services Can Help Make Valentine's Day Smoke-Free 3
... The new E300 Corneal ... diverse range of clinical procedures ... Refractive Surgery and Contact Lens ... compact cone design, the E300 ...
Egg-Shaped Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be e...
... The S7 with Discrete Technology ... plus unmatched scaffolding. Proprietary Secure Technology ... proximal pillows that partially encapsulate the ... Discrete Technology is designed to minimize ...
Increased stent scaffolding at the proximal end gives optimal lumen support and 6F guide catheter compatibility and improved tracking offer excellent deliverability. Customized balloon lengths for ea...
Medicine Products: